129 related articles for article (PubMed ID: 37860418)
1. Retracted: CAMPO Precision128 Max ENERGY Spectrum CT Combined with Multiple Parameters to Evaluate the Benign and Malignant Pleural Effusion.
Healthcare Engineering JO
J Healthc Eng; 2023; 2023():9841457. PubMed ID: 37860418
[TBL] [Abstract][Full Text] [Related]
2. CAMPO Precision128 Max ENERGY Spectrum CT Combined with Multiple Parameters to Evaluate the Benign and Malignant Pleural Effusion.
Zhang T; Wu C; Li Z; Ding Y; Wen L; Wang L
J Healthc Eng; 2021; 2021():5526977. PubMed ID: 33728032
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "CAMPO Precision128 Max ENERGY Spectrum CT Combined with Multiple Parameters to Evaluate the Benign and Malignant Pleural Effusion".
Zhang T; Wu C; Li Z; Ding Y; Wen L; Wang L
J Healthc Eng; 2021; 2021():9791042. PubMed ID: 34976332
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis between benign and malignant pleural effusion with dual-energy spectral CT.
Zhang X; Duan H; Yu Y; Ma C; Ren Z; Lei Y; He T; Zhang M
PLoS One; 2018; 13(4):e0193714. PubMed ID: 29641601
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
[TBL] [Abstract][Full Text] [Related]
6. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
Sun Y; Yu H; Ma J; Lu P
PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.
Nakajima R; Abe K; Sakai S
Medicine (Baltimore); 2015 Jul; 94(29):e1010. PubMed ID: 26200610
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion.
Yang MF; Tong ZH; Wang Z; Zhang YY; Xu LL; Wang XJ; Li W; Wu XZ; Wang W; Zhang YH; Jiang T; Shi HZ
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1457-1467. PubMed ID: 30903197
[TBL] [Abstract][Full Text] [Related]
9. Can PET/CT be used more effectively in pleural effusion evaluation?
Simsek FS; Yuksel D; Yaylali O; Aslan HS; Kılıçarslan E; Bir F; Arslan M; Can FE; Ugurlu E
Jpn J Radiol; 2021 Dec; 39(12):1186-1194. PubMed ID: 34165683
[TBL] [Abstract][Full Text] [Related]
10. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
11. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography.
Toaff JS; Metser U; Gottfried M; Gur O; Deeb ME; Lievshitz G; Mercer D; Even-Sapir E
Invest Radiol; 2005 Apr; 40(4):204-9. PubMed ID: 15770138
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of SHOX2, RASSF1A gene methylation combined with CEA level detection in malignant pleural effusion.
Chen S; Huang K; Zou L; Chen L; Hu P
BMC Pulm Med; 2023 May; 23(1):160. PubMed ID: 37158875
[TBL] [Abstract][Full Text] [Related]
13. Retracted: Diagnostic Value of Model-Based Iterative Algorithm in Tuberculous Pleural Effusion.
Healthcare Engineering JO
J Healthc Eng; 2023; 2023():9780245. PubMed ID: 38094842
[TBL] [Abstract][Full Text] [Related]
14. [Clinical role of F-18 FDG PET/CT in differentiating malignant and benign pleural effusion in patients with lung cancer].
Liao R; Yang X; Wang S; Zhou Q; Nie Q; Zhong W; Dong S; Wu Y
Zhongguo Fei Ai Za Zhi; 2012 Nov; 15(11):652-5. PubMed ID: 23164351
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species modulator 1, a novel protein, combined with carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Chen X; Zhang N; Dong J; Sun G
Tumour Biol; 2017 May; 39(5):1010428317698378. PubMed ID: 28459208
[TBL] [Abstract][Full Text] [Related]
16. Retracted: Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC.
International EM
Emerg Med Int; 2024; 2024():9846256. PubMed ID: 38298996
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of LUNX mRNA and VEGF mRNA in pleural fluid for differentiating benign from malignant origin.
Bao QL; Li J; Sun W; Jiang HG; Zhu LR; Wang Y
Jpn J Clin Oncol; 2014 Dec; 44(12):1198-205. PubMed ID: 25425729
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer. A cytopathological correlation.
Letovanec I; Allenbach G; Mihaescu A; Nicod Lalonde M; Schmidt S; Stupp R; Fitting JW; Boubaker A; Ris HB; Prior JO
Nuklearmedizin; 2012; 51(5):186-93. PubMed ID: 22584348
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion].
Li H; Fu J; Xiu Y; Zhou Q
Zhongguo Fei Ai Za Zhi; 2010 Jun; 13(6):652-4. PubMed ID: 20681457
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
Ak G; Tomaszek SC; Kosari F; Metintas M; Jett JR; Metintas S; Yildirim H; Dundar E; Dong J; Aubry MC; Wigle DA; Thomas CF
Biomed Res Int; 2015; 2015():635748. PubMed ID: 25756049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
